U.S. markets closed

Annovis Bio, Inc. (ANVS)

NYSE American - NYSE American Delayed Price. Currency in USD
Add to watchlist
93.45+3.40 (+3.78%)
At close: 4:00PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Commodity Channel Index

Commodity Channel Index

Previous Close90.05
Open88.68
Bid90.17 x 1300
Ask93.00 x 900
Day's Range86.58 - 95.20
52 Week Range3.84 - 100.65
Volume572,334
Avg. Volume1,243,603
Market Cap649.222M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est45.00
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • These 2 Biotech Stocks Are Up 1,000% This Year
    Motley Fool

    These 2 Biotech Stocks Are Up 1,000% This Year

    With all of the recent news around a new treatment for Alzheimer's disease (AD), the huge gains by smaller biotechs developing treatments can get lost. Now that the Food and Drug Administration has approved Biogen's (NASDAQ: BIIB) Aduhelm despite its mixed results, it theoretically made it much easier for new treatments to get the green light. Unlike most AD drugs, Annovis Bio's ANVS401 isn't designed to get rid of amyloid in the brain.

  • Ignore Biogen: 3 Reasons These Stocks Will Be Better Alzheimer's Investments
    Motley Fool

    Ignore Biogen: 3 Reasons These Stocks Will Be Better Alzheimer's Investments

    When the Food and Drug Administration (FDA) approved Biogen's (NASDAQ: BIIB) aducanumab -- now marketed as Aduhelm -- for treating Alzheimer's Disease, it marked the end of a long drought. No matter how that turns out, the low bar for approval set by the FDA is likely to open the floodgates for Alzheimer's treatments. It has investors in Cassava Sciences (NASDAQ: SAVA) and Annovis Bio (NYSEMKT: ANVS) excited about their candidates, which are currently in clinical trials.

  • Annovis Bio to Present at 2021 BIO Digital
    Newsfile

    Annovis Bio to Present at 2021 BIO Digital

    Berwyn, Pennsylvania--(Newsfile Corp. - June 10, 2021) - Annovis Bio, Inc. (NYSE American: ANVS), ("Annovis" or the "Company"), a clinical-stage drug platform company addressing Alzheimer's disease (AD), Parkinson's disease (PD) and other neurodegenerative diseases, today announced its participation in 2021 BIO Digital, the premier biotech event, taking place online June 10-11 & 14-18, 2021.A corporate presentation by Maria L. Maccecchini, Ph.D., CEO of Annovis Bio, will be available to register